Khondrion Announces First Patients Dosed in Phase IIb Study of Sonlicromanol for Mitochondrial Diseases

NIJMEGEN, the Netherlands, Jan. 27 (Korea Bizwire) – Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its phase IIb KHENERGYZE study of Sonlicromanol (previously known as KH176), its wholly-owned lead asset in development to treat a range of mitochondrial diseases. [...]